SNCG Antibody

1. LncRNA-AK058003 can reduce the expression of mRNA stabilizing protein HuR and act as a precursor of miR-15a to suppress gamma-synuclein-mediated cell proliferation and the metastasis of hepatocellular carcinoma. PMID: 28035067
2. Results demonstrated that urine SNCG can discriminate bladder cancer from urinary diseases, and is a useful prognosticator of postsurgical recurrence. PMID: 27223068
3. A positive SNCG may serve as a potential marker to identify breast cancer patients who are less likely to benefit from radiotherapy PMID: 27595752
4. This largest collection of USCs to date demonstrates that SNCG was associated with poor survival in univariate analyses. SNCG does not predict survival outcome independent of p53 and p16 in models that jointly consider multiple markers. PMID: 27926776
5. SNCG expression in ovarian cancer is frequent in patients with high-risk features, but it does not correlate with chemotherapy response, overall survival, or progression-free survival. PMID: 27809878
6. High synoretin expression is associated with non-small cell lung cancer. PMID: 27655287
7. Study shows an overexpression of SNCG in bladder cancer (BC) tissues which correlates positively with neoplasm recurrence. SNCG seems a good marker to predict recurrence of BC, but not a reliable one for staging or prediction of survival rate. PMID: 26976983
8. down-regulation of gamma-synuclein reduces the protein level of PLCbeta but increases the transcript level over 40 fold PMID: 26521046
9. the conformational dynamics of ERalpha36 in the absence and presence of Hsp90 and gammaSyn, is reported. PMID: 26299756
10. SNCG may promote MCF7 cell migration through activating the Erk pathway and breaking cell-cell junctions. PMID: 25997706
11. Data suggest that both BubR1 and SNCG may be promising predictive marker rather than prognostic marker in patients with breast cancer. PMID: 26191236
12. High gamma-Synuclein expression is associated with invasiveness in colon adenocarcinoma. PMID: 25956278
13. Synuclein-gamma shares some, but not all, gene regulators with leptin and is a PPARgamma target in adipocytes but not dorsal root ganglia neurons. PMID: 25756178
14. These results advance our understanding of the role of lncRNA-AK058003 as a regulator of hypoxia signaling, and this newly identified hypoxia/lncRNA-AK058003/SNCG pathway may help in the development of new therapeutics. PMID: 25499222
15. SNCG is highly expressed in bladder cancer tissue and its expression is stage-specific, but it is not helpful for predicting outcome in bladder cancer patients. PMID: 25479371
16. Results indicate that SNCG specifically interacts with Akt and mTOR and protects Akt/mTOR stability and function under stressful conditions when the activity of Hsp90 is blocked. PMID: 24954510
17. SNCG, MAP2, SDF-1 and CXCR4 may play an important role in the carcinogenesis, progression, invasion and metastasis of gastric adenocarcinoma. PMID: 25400739
18. Our results are the first to suggest that SNCG is a new independent predictor for poor prognosis in EC patients in the literature. PMID: 25142230
19. SNCG is actively secreted by cancer cells via an unconventional secretion pathway and contributes to aggressive phenotypes of cancer cells. PMID: 25229320
20. These data show that SNCG renders AMD resistance by inhibiting BubR1 activity and attenuating SAC function. PMID: 24431077
21. even though purified gamma-synuclein form oligomers, when binding partners are present, as in cells, it dissociates to a monomer to bind these partners, which in turn may modify protein function and integrity PMID: 24367999
22. Data indicate that micro-RNAs might provide cell-specific regulation of gamma-synuclein expression. PMID: 24040069
23. SNCG expression indicates a much poorer prognosis of TNBC. PMID: 23696021
24. These results provide strong evidence that suggests gamma-synuclein plays a positive role in the progression of colorectal cancer. PMID: 23970348
25. Gamma-synuclein expression was an independent predictor of the neoadjuvant chemotherapy objective response rate. PMID: 23696593
26. Serum synuclein-gamma provided a promising diagnostic biomarker for early detection and was a complementary biomarker of carcinoembryonic antigen and/or CA19-9 in gastrointestinal and esophageal cancer. PMID: 22440249
27. Compared to controls there were lower levels of gamma synuclein in the visual cortex from dementia with Lewy bodies patients. PMID: 23242284
28. gamma-synuclein has a role in promoting a more robust G protein Galphaq activation of PLCbeta2 PMID: 22905097
29. Thermodynamic studies in conjunction with EPR confirm that alpha-synuclein, beta-synuclein, and gamma-synuclein bind copper(II) in a high affinity 1:1 stoichiometry. PMID: 21117662
30. SNCG can serve as a marker for the potential of the tumor cell for the rapid spreading and metastazing of the non-differentiated tumors. PMID: 22294286
31. SNCG biomarker has independently poor prognostic value for patients with lymph node metastasis. PMID: 22261620
32. Data from our in vivo study showed a decrease in tumor growth and weight in mice injected with SNCG-silenced NOZ cells. Together, these findings suggest that SNCG plays an important role in the progression of GBC PMID: 22201822
33. Overexpression of SNCG seemed to be a predictor biomarker for aggressive tumor behavior and adverse outcome in patients with endometrial cancer. PMID: 22015044
34. gamma-synuclein is a promising new adjunct marker for identifying reactive follicular dendritic cells and for diagnosing follicular dendritic cell sarcoma and benign and malignant vascular tumors. PMID: 21959308
35. SNCG shRNA effectively suppressed breast cancer cell formation in vivo and may be a useful clinical strategy to control breast cancer. PMID: 21740810
36. SNCG interacts only with the 18kDa region of Hsp70 substrate binding domain and the TPR motif of BubR1. Based on the interactions of SNCG with N-BubR1 and ANK peptide, the common residues of SNCG that mediate these interactions were identified. PMID: 20437261
37. The upregulation of gamma-synuclein expression in colorectal cancer is primarily attributed to the demethylation of CpG islands. PMID: 20577925
38. SNCG overexpression is associated with colon cancer. PMID: 20604972
39. Results indicate that ER-alpha36 is a new member of the ER-alpha family that mediates membrane-initiated estrogen signaling and that synuclein gamma can replace the function of heat shock protein 90. PMID: 20595634
40. The reciprocal regulation of gamma-synuclein and IGF-I receptor expression creates a circuit that modulates IGF-I signaling. PMID: 20670935
41. members of the synuclein gene family, particularly SNCA and SNCG, affect the risk of developing diffuse lewy body disease. PMID: 20697047
42. Gamma-synuclein protein is valuable for evaluation of progression of colorectal carcinoma; it is more sensitive to predict advanced stage and lymph node invasion when combined with either alpha- or beta-synuclein protein. PMID: 20043104
43. gamma-synuclein may play a positive role in the progression of colorectal cancer PMID: 19859996
44. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins PMID: 11812782
45. strong evidence that AP1 plays an overriding role in the transcription of the BCSG1 gene and that blockade of AP1 transactivation down-regulates BCSG1 expression and suppresses tumor phenotype PMID: 12072430
46. role in promoting cancer cell survival and inhibition of stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways PMID: 12121974
47. data demonstrated a moderate elevation of matrix metalloproteinases-2 and significant upregulation of matrix metalloproteinases-9 in stable cell lines overexpressing gamma-synuclein PMID: 12559990
48. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. PMID: 12566312
49. In high-grade glial tumors. Found in all anaplastic ependymomas but in only 33% of ependymomas and 16% of myxopapillary ependymomas. In 63% of glioblastomas but not in other astrocytic tumors. No gamma-synuclein in medulloblastomas. PMID: 12783249
50. SNCG is required for efficient ER-alpha signaling in brest cancer. PMID: 12873981

Show More

Hide All

HGNC: 11141

OMIM: 602998

KEGG: hsa:6623

STRING: 9606.ENSP00000361087

UniGene: Hs.349470